Evaluation Of The Effect Of SGLT-2 Inhibitors On Atrial Fibrillation Recurrence In Diabetic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-02

Study Completion Date

2024-10-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Consecutive DCCV was performed until to achieve 120 patients in SR (60 DM patients who used SGLT-2 inhibitors and 60 DM patients who did not use SGLT-2 inhibitors). Patients defined as SGLT-2 inhibitor user group and control group. The two groups were monitored for AF recurrence on the first day, then at one, three, and six months after CV.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Sodium-glucose Cotransporter 2 Inhibitors on Post-operative Atrial Fibrillation in Cardiothoracic Surgery

NCT06251453

Atrial Fibrillation

UNKNOWN

Sodium-glucose Co-transporter 2 Inhibitors Effects in Failing Heart Patients

NCT03977116

Diabetes Mellitus Heart Failure Ventricular Arrythmia

COMPLETED PHASE4

SGLT2i As Anti Arrhythmic Therapy to Prevent Sudden Cardiac Deaths.

NCT03366181

Heart Failure ICD Diabetes Mellitus Type 2 +1 more

COMPLETED

Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling in Diabetic Patients

NCT07186153

SGLT 2 Inhibitors

NOT_YET_RECRUITING

Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation

NCT06740786

Atrial Fibrillation (AF)

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus Atrial Fibrillation (AF)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SGLT-2 inhibitor user

patients with diabetes mellitus, atrial fibrillation and using SGLT-2 inhibitor

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients \> 18 years and \< 90 years,
* Patient diagnosed with DM
* Patient underwent electrical cardioversion due to AF and was restored to sinus rhythm

Exclusion Criteria

* patient who are not suitable for anticoagulant use,
* have thyroid dysfunction,
* glomerular filtration rate ≤ 25 ml/min/1.73 m²,
* patients whose sinus rhythm cannot be achieved with electrical cardioversion,
* malignancy patients,
* patients with acute or chronic inflammatory disease,
* patients with peripheral artery disease,
* patients with pacemakers,
* patients with advanced valve stenosis or insufficiency,
* patients who have had coronary bypass surgery,
* patients with percutaneous or surgical bioprosthesis or metallic valve surgery.

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No